Sandoz Breaks Off Digital Deal With Pear
Decision Follows Change In Sandoz Leadership
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
You may also be interested in...
Iris Zemzoum, Novartis Pharma's president for Asia Pacific, Middle East and Africa, outlines how the company is shaping its strategy in the region, which comes with “extremes” in market profiles, via a distinct archetype that factors in commonalities between national healthcare systems. The company is also progressing interesting initiatives in digital therapeutics.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.